{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T04:26:10Z","timestamp":1767155170890,"version":"3.40.5"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejps.2018.12.004","type":"journal-article","created":{"date-parts":[[2018,12,8]],"date-time":"2018-12-08T15:44:38Z","timestamp":1544283878000},"page":"209-214","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"128","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8471-9826","authenticated-orcid":false,"given":"Tomoyuki","family":"Mizuno","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maureen M.","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander A.","family":"Vinks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejps.2018.12.004_bb0005","doi-asserted-by":"crossref","first-page":"e20153257","DOI":"10.1542\/peds.2015-3257","article-title":"Efficacy and safety of sirolimus in the treatment of complicated vascular anomalies","volume":"137","author":"Adams","year":"2016","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejps.2018.12.004_bb0010","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1124\/dmd.107.015511","article-title":"Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes","volume":"35","author":"Aitken","year":"2007","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.12.004_bb0015","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1182\/blood-2005-03-0929","article-title":"Rapamycin stimulates apoptosis of childhood acute lymphoblastic leukemia cells","volume":"106","author":"Avellino","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejps.2018.12.004_bb0020","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/S1470-2045(08)70229-8","article-title":"Bone-marrow relapse in paediatric acute lymphoblastic leukaemia","volume":"9","author":"Bailey","year":"2008","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejps.2018.12.004_bb0025","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Paediatr. Drugs"},{"key":"10.1016\/j.ejps.2018.12.004_bb0030","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/bjh.14529","article-title":"m-TOR inhibitors and their potential role in haematological malignancies","volume":"177","author":"Calimeri","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2018.12.004_bb0035","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0041365","article-title":"Cytokine and chemokine levels in patients with severe fever with thrombocytopenia syndrome virus","volume":"7","author":"Deng","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.ejps.2018.12.004_bb0040","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1124\/dmd.111.038679","article-title":"Effects of interleukin\u20116 (IL-6) and an anti-IL-6 monoclonal antibody on drug-metabolizing enzymes in human hepatocyte culture","volume":"39","author":"Dickmann","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.ejps.2018.12.004_bb0045","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.2165\/00003088-200645110-00007","article-title":"Sirolimus population pharmacokinetic\/pharmacogenetic analysis and bayesian modelling in kidney transplant recipients","volume":"45","author":"Djebli","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.12.004_bb0050","doi-asserted-by":"crossref","first-page":"S22","DOI":"10.1053\/ajkd.2001.27838","article-title":"Safety and efficacy of TOR inhibitors in pediatric renal transplant recipients","volume":"38","author":"Ettenger","year":"2001","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.ejps.2018.12.004_bb0055","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S0009-9236(98)90045-5","article-title":"Population pharmacokinetics of sirolimus","volume":"63","author":"Ferron","year":"1998","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.12.004_bb0060","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/clpt.2009.308","article-title":"Therapeutic protein-drug interactions and implications for drug development","volume":"87","author":"Huang","year":"2010","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.12.004_bb0065","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1056\/NEJMra1400972","article-title":"Acute lymphoblastic leukemia in children","volume":"373","author":"Hunger","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.12.004_bb0070","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/j.1399-3046.2005.00324.x","article-title":"Sirolimus in pediatric patients: results in the first 6\u202fmonths post-renal transplant","volume":"9","author":"Hymes","year":"2005","journal-title":"Pediatr. Transplant."},{"key":"10.1016\/j.ejps.2018.12.004_bb0075","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s12985-015-0392-3","article-title":"Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative of severe disease","volume":"12","author":"Jansen van Vuren","year":"2015","journal-title":"Virol. J."},{"key":"10.1016\/j.ejps.2018.12.004_bb0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.ejps.2018.01.009","article-title":"Development and applications of a physiologically-based model of paediatric oral drug absorption","volume":"115","author":"Johnson","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.12.004_bb0085","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomized multicenter study. The Rapamune US Study Group","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.ejps.2018.12.004_bb0090","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1056\/NEJMra035092","article-title":"Developmental pharmacology-drug disposition, action, and therapy in infants and children","volume":"349","author":"Kearns","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejps.2018.12.004_bb0095","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.ejps.2018.12.004_bb0100","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1038\/clpt.2013.79","article-title":"A physiologically based pharmacokinetic modeling approach to predict disease-drug interactions: suppression of CYP3A by IL-6","volume":"94","author":"Machavaram","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejps.2018.12.004_bb0105","doi-asserted-by":"crossref","first-page":"573","DOI":"10.2165\/00003088-200140080-00002","article-title":"Clinical pharmacokinetics of sirolimus","volume":"40","author":"Mahalati","year":"2001","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ejps.2018.12.004_bb0110","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1016\/j.ejps.2017.05.037","article-title":"Model-based precision dosing of sirolimus in pediatric patients with vascular anomalies","volume":"109S","author":"Mizuno","year":"2017","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejps.2018.12.004_bb0115","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1038\/clpt.2008.302","article-title":"Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics","volume":"85","author":"Morgan","year":"2009","journal-title":"Clin. Pharmacol. Ther."},{"issue":"Suppl. 5","key":"10.1016\/j.ejps.2018.12.004_bb0120","doi-asserted-by":"crossref","first-page":"S178","DOI":"10.1086\/317513","article-title":"Circulating cytokines as mediators of fever","volume":"31","author":"Netea","year":"2000","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ejps.2018.12.004_bb0125","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1038\/leu.2008.251","article-title":"Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children's Oncology Group study","volume":"22","author":"Nguyen","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.ejps.2018.12.004_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27062","article-title":"Phase I trial of the mTOR inhibitor everolimus in combination with multi-agent chemotherapy in relapsed childhood acute lymphoblastic leukemia","volume":"65","author":"Place","year":"2018","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejps.2018.12.004_bb0140","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1111\/bjh.14569","article-title":"A phase 1 trial of temsirolimus and intensive re-induction chemotherapy for 2nd or greater relapse of acute lymphoblastic leukaemia: a Children's Oncology Group study (ADVL1114)","volume":"177","author":"Rheingold","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ejps.2018.12.004_bb0145","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1097\/FTD.0b013e318286dd3f","article-title":"Population pharmacokinetics of sirolimus in pediatric patients with neurofibromatosis type 1","volume":"35","author":"Scott","year":"2013","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.ejps.2018.12.004_bb0150","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1128\/AAC.46.9.3091-3093.2002","article-title":"Voriconazole inhibition of the metabolism of tacrolimus in a liver transplant recipient and in human liver microsomes","volume":"46","author":"Venkataramanan","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ejps.2018.12.004_bb0155","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1002\/pbc.24873","article-title":"Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study","volume":"61","author":"Weiss","year":"2014","journal-title":"Pediatr. Blood Cancer"},{"key":"10.1016\/j.ejps.2018.12.004_bb0160","doi-asserted-by":"crossref","DOI":"10.1038\/psp.2012.18","article-title":"Nonlinear population pharmacokinetics of sirolimus in patients with advanced cancer","volume":"1","author":"Wu","year":"2012","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/j.ejps.2018.12.004_bb0165","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1177\/009127009903901107","article-title":"The effect of a high-fat meal on the oral bioavailability of the immunosuppressant sirolimus (rapamycin)","volume":"39","author":"Zimmerman","year":"1999","journal-title":"J. Clin. Pharmacol."}],"container-title":["European Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718305396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0928098718305396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T23:31:28Z","timestamp":1694475088000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0928098718305396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":32,"alternative-id":["S0928098718305396"],"URL":"https:\/\/doi.org\/10.1016\/j.ejps.2018.12.004","relation":{},"ISSN":["0928-0987"],"issn-type":[{"type":"print","value":"0928-0987"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Significant effect of infection and food intake on sirolimus pharmacokinetics and exposure in pediatric patients with acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejps.2018.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}